文献速递治疗药物监测与药物基因组学特殊人群用药

儿童青少年利培酮治疗结局的基因组学洞察:农村青少年精神专科医院经验

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth.
PubMed 文献 · Clin Pharmacol Ther · 2026-04-14

本研究在161例农村精神专科医院住院的儿童青少年患者中开展全基因组关联研究(GWAS),回顾性分析利培酮治疗结局。41.0%患者停用利培酮,但利培酮维持时间长于除喹硫平外的其他抗精神病药;女性及急性项目患者停药更快。鉴定出9个与利培酮治疗时长、停药频率、最大剂量、再入院时间及住院时长相关的遗传变异。

要点

  • 41.0%患儿停用利培酮,但利培酮持续治疗时间优于除喹硫平外的其他抗精神病药。
  • 女性患者和急性项目患者停用利培酮更快。
  • 发现9个遗传变异与利培酮治疗时长、停药频率、最大剂量、再入院时间及住院时长相关。

核心结论

  • 本研究为首个儿童人群利培酮反应GWAS,揭示利培酮反应的生物学复杂性,推动精准抗精神病药物治疗。
  • 在社区医疗机构开展研究具有高价值,提示需将研究扩展到学术医学中心之外。

研究设计与样本

  • 研究类型:全基因组关联研究(GWAS),回顾性收集临床、人口学和治疗结局数据并纳入预测模型。
  • 研究对象:在农村儿科医院接受住院治疗的儿童青少年患者,n=161。

主要发现

  • 41.0%患者停用利培酮;利培酮维持时间长于其他抗精神病药,但喹硫平除外。
  • 女性患者停药更快;急性项目患者相比住院部患者停药更快。
  • 与利培酮治疗时长和停药频率相关的变异:rs10270303(PTPRN2内含子变异)。
  • 与利培酮最大剂量相关的变异:rs6014649(CBLN4与MC3R间基因间变异)、rs56261530(SHD同义变异)。
  • 与再入院时间相关的变异:rs35722167(UGT2A3与UGT2B7间基因间变异)、rs62382382(SGCD内含子变异)、rs62466698(BET1与GNG11间基因间变异)、rs1152938(CPM内含子变异);与住院时长相关的变异:rs117426990(TMX3 3'-UTR变异)、rs5956073(DOCK11与LINC01285间基因间变异)。

临床怎么用

  • 临床可关注女性及急性项目患儿利培酮停药风险较高,加强监测与随访。
  • 遗传变异信息有望辅助预测利培酮治疗时长、剂量需求、再入院及住院时长,推动个体化用药。

局限性

  • 回顾性研究设计,样本量有限(n=161),结论需更大队列验证。
  • 研究人群为农村精神专科医院住院儿童青少年,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited. We conducted a genome-wide association study (GWAS) to investigate genetic predictors of risperidone response in pediatric patients (n = 161) who received inpatient care at a pediatric hospital in a rural setting. Clinical, demographic, and treatment outcomes data, collected retrospectively, were incorporated into predictive models. While 41.0% of patients discontinued risperidone, patients remained on risperidone longer than other antipsychotics, with the exception of quetiapine. Female patients discontinued more quickly, as did patients in the acute program compared to residential. We identified nine genetic variants associated with risperidone outcomes: duration of risperidone treatment and frequency of risperidone discontinuation (rs10270303, intronic variant, PTPRN2), maximum risperidone dose (rs6014649, intergenic variant between CBLN4 and MC3R; rs56261530, synonymous variant, SHD), time to readmission (rs35722167, intergenic variant between UGT2A3 and UGT2B7; rs62382382, intronic variant, SGCD; rs62466698, intergenic variant between BET1 and GNG11; rs1152938, intronic variant, CPM), and duration of hospital stay (rs117426990, 3'-UTR variant, TMX3; rs5956073, intergenic variant between DOCK11 and LINC01285). Our study is the first GWAS of risperidone response in pediatric populations, which provides insights into the biological complexity of risperidone response, as well as moving toward precision antipsychotic treatment. Our study demonstrates the high value of conducting research in a community-based setting and highlights the need to expand research studies beyond academic medical centers.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Staples JW, Killam SR, Brown KE, et al. Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth. Clin Pharmacol Ther. 2026. PMID: 41979230. doi:10.1002/cpt.70287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。